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BACKGROUND: Cardiac sympathetic denervation (CSD) has been used as a bailout strategy for refractory ventricular tachycar-
dia (VT). Risk of VT recurrence in patients with scar-related monomorphic VT referred for CSD and the extent to which CSD 
can modify this risk is unknown. We aimed to quantify arrhythmia recurrence risk and impact of CSD in this population.
METHODS AND RESULTS: Adjusted competing risk time to event models were developed to adjust for risk of VT recurrence and 
sustained VT/implantable cardioverter–defibrillator shocks after VT ablation based on patient comorbidities at the time of VT 
ablation. Adjusted VT and implantable cardioverter–defibrillator shock recurrence rates were estimated for the subgroup who 
subsequently required CSD after ablation. The expected adjusted recurrence rates were then compared with the observed 
rates after CSD. Data from 381 patients with scar-mediated monomorphic VT who underwent VT ablation were analyzed, 
excluding patients with polymorphic VT. Sixty eight patients underwent CSD for recurrent VT. CSD reduced the expected 
adjusted VT recurrence rate by 36% (expected rate of 5.61 versus observed rate of 3.58 per 100 person-months, P=0.01) and 
the sustained VT/implantable cardioverter–defibrillator shock rates by 34% (expected rate of 4.34 versus observed 2.85 per 
100 person-months, P=0.03). The median number of sustained VT/implantable cardioverter–defibrillator shocks in the year 
before versus the year after CSD was reduced by 90% (10 versus 1, P<0.0001).
CONCLUSIONS: Patients referred for CSD for refractory scar-mediated monomorphic VT are at a higher risk of VT recurrence 
after ablation as compared with those not requiring CSD, mostly because of their cardiac comorbidities. CSD significantly 
reduced both the expected risk of recurrences and VT burden.
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Implantable cardioverter–defibrillators (ICDs) reduce the risk of sudden cardiac death due to ventricular tachycardia (VT)/ventricular fibrillation (VF) in patients 
with reduced left ventricular ejection faction (LVEF).1 
However, recurrent ICD shocks increase morbidity 
and mortality and decrease quality of life.2 Therefore, 
catheter ablation has emerged as the leading strategy 
to reduce ICD shocks. Despite advances in ablation 
strategy, however, a significant subset of patients con-
tinue to experience recurrent VT.
Cardiac sympathetic denervation (CSD) has been 
reported to reduce VT inducibility and ischemia-driven 
ventricular arrhythmias in animal models of myocardial 
infarction3,4 and decrease the burden of ICD shocks 
in patients with cardiomyopathy and recurrent VT/VF.5 
However, given a heterogenous population reported in 
Correspondence to: Marmar Vaseghi, MD, PhD, UCLA Cardiac Arrhythmia Center, 100 Medical Plaza, Suite 660, Los Angeles, CA 90095. E-mail: mvaseghi@
mednet.ucla.edu
For Sources of Funding and Disclosures, see page 13.
© 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative 
Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and 
is not used for commercial purposes. 




 http://ahajournals.org by on A
pril 13, 2021
J Am Heart Assoc. 2021;10:e018371. DOI: 10.1161/JAHA.120.018371 2
Dusi et al Bailout Sympathetic Denervation for Monomorphic VT
previous case series, which included cardiomyopathy 
patients with VF, polymorphic VT, and monomorphic 
VT, controversy regarding the efficacy of CSD in the 
setting of scar-mediated monomorphic ventricular 
tachycardia (MMVT) exists. In addition, clinical trials 
comparing CSD with standard of care in patients with 
VT who have structural heart disease (SHD) are lack-
ing. Therefore, the impact of CSD on VT recurrence 
rates over time is unknown.5,6 Retrospective case se-
ries have relied primarily on analysis of VT burden be-
fore versus after the procedure,5–10 and it is unknown 
what the rate of VT recurrence would have been in 
these patients, if CSD had not been performed, in 
order to quantify the benefit of CSD. Finally, reported 
patients had many comorbidities, which were not ac-
counted for in previous studies,5–10 and likely affected 
outcomes, making it difficult to delineate the efficacy 
of CSD. The purpose of this study was to quantify the 
impact of CSD on outcomes in patients with SHD and 
MMVT referred for catheter ablation, using a compet-
ing risk analysis to adjust for comorbidities.
METHODS
Data Collection
Retrospective data collection was approved by the UCLA 
institutional review board (#16-001417). The data that 
support the findings of this study are available from the 
corresponding author on reasonable request. Data from 
consecutive patients undergoing VT ablation for scar-me-
diated MMVT between 2007 and 2018 were analyzed. In 
the subgroup that required CSD, dynamic clinical data 
were also collected at the time of presentation for CSD. 
Notably, patients with any spontaneously occurring poly-
morphic VT, including those with both MMVT and poly-
morphic VT/VF, were excluded. Patients with MMVT who 
had polymorphic VT/VF induced with either invasive or 
noninvasive programmed electrical stimulation were still 
included in the study. Patients with focal monomorphic VT 
likely related to abnormal automaticity or triggered activity 
as well as those with bundle-branch reentrant VT were 
excluded from the study, independent of the presence of 
scar. SHD was defined by LVEF <50% or by presence of 
ventricular scar, hypertrophy, or inflammatory conditions. 
Presence of myocardial scar was identified with prepro-
cedural imaging and confirmed with electroanatomical 
mapping, using standard endocardial and/or epicardial 
voltage criteria.11 VT storm was defined as ≥3 sustained 
VT episodes or ICD therapies in 24 hours.
In patients with a history of multiple VT ablations, 
available data from the most recent (last) ablation pro-
cedure (referred to as the index VT ablation) at our cen-
ter were used. The date of the index ablation procedure 
was used as the beginning of follow-up. In addition, the 
type of presentation at the time of index ablation was 
evaluated. Presentations were defined as: (1) elective: 
outpatient referral for ablation; (2) urgent: requiring hos-
pitalization for VT/ICD shock(s) leading to referral for 
ablation during the same hospitalization; and (3) emer-
gent: cardiocirculatory arrest and/or need for mechani-
cal (including intra-aortic balloon pump, extracorporeal 
membrane oxygenation, or impella) support at the time 
of hospitalization for VT/ICD shock(s).
Electrophysiology Study and Ablation
Substrate-based ablation of scar guided by electro-
anatomic mapping was the primary strategy used in 
CLINICAL PERSPECTIVE
What Is New?
• This is the first study to quantify arrhythmia 
recurrence risk and impact of cardiac sympa-
thetic denervation (CSD) exclusively in patients 
with scar-related monomorphic ventricular 
tachycardia (VT) referred for VT ablation and 
then CSD, excluding patients with any evidence 
of polymorphic VT.
• It demonstrates that patients undergoing CSD 
for refractory scar-mediated monomorphic 
VT are at a higher risk of VT recurrence after 
ablation as compared with those not referred 
for CSD, because of their underlying cardiac 
comorbidities.
• Nonetheless, CSD significantly reduced both 
the expected risk of ventricular arrhythmia re-
currences and VT burden.
What Are the Clinical Implications?
• Despite the higher risk of VT recurrence in pa-
tients referred for CSD, this procedure can be 
an effective antiarrhythmic strategy for patients 
with ablation and drug refractory scar-related 
monomorphic VT.
• CSD is effective in reducing the burden of 
monomorphic VT in patients with ischemic as 
well as nonischemic cardiomyopaty.
Nonstandard Abbreviations and Acronyms
AAD antiarrhythmic drug
ATP anti-tachycarida pacing
CSD cardiac sympathetic denervation
MMVT monomorphic ventricular tachycardia
NICM nonischemic cardiomyopathy
NYHA New York Heart Association
OHT orthotopic heart transplantation
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all patients. If VT was induced and hemodynamically 
tolerated, activation and entrainment mapping were 
also performed in addition to substrate ablation to 
target appropriate ablation sites. Electroanatomic 
mapping was performed using CARTO (Biosense 
Webster) or NAVX (St. Jude Medical) with standard 
low-voltage settings (<1.5 mV) for border zone iden-
tification.12 Substrate modification/ablation of scar 
containing areas with late activation or split, fraction-
ated, or isolated late electrograms was performed in 
all patients.13–15 In addition, attempt at induction of VT 
was made with programmed ventricular stimulation 
using 2 drive cycle lengths, with up to 2 sites and 3 
extrastimuli.
The clinical VT followed by nonclinical VTs were 
targeted for ablation. Pace mapping was used to tar-
get potential VT exit sites that matched the clinical 
VT in morphology, in patients who were inducible for 
VT.16 If VT was not inducible at the beginning of the 
case, then only substrate mapping and ablation were 
performed.
If percutaneous epicardial access could not be ob-
tained because of prior cardiac surgery, the epicardium 
was accessed surgically. Catheter ablation was per-
formed using open-irrigated catheters (ThermoCool, 
ThermoCool SF, or Navistar RMT [Biosense-Webster] 
or FlexAbility o FlexAbility Sensor-Enabled [Abbott]) 
or closed-loop irrigated catheters (Chilli, Boston 
Scientific).
Noninducibility of VT served as the desired proce-
dural end point, and programmed stimulation was per-
formed at the end of the procedure, unless prohibited 
by hemodynamic instability or procedural duration.11 
Epicardial mapping was performed in patients with 
epicardial scar noted on preprocedural imaging and/
or an epicardial VT exit site suspected based on ECG 
morphology of VT or in patients with previously failed 
endocardial ablation.
Cardiac Sympathetic Denervation
CSD was performed via a minimally invasive (video- or 
robot-assisted) thoracoscopic surgical approach, as 
previously reported.5,17 Three 1.5-cm incisions were 
made in the ipsilateral chest wall under general anes-
thesia using single-lung inflation. After ipsilateral lung 
deflation, the sympathetic chain was identified behind 
the parietal pleura and dissected, and the lower one 
half to one third of the stellate ganglion as well as T2 
to T4 thoracic ganglia were removed. In addition, when 
present, the nerve of Kuntz was divided.18 Histological 
confirmation of neuronal cell bodies within the ganglia 
was obtained via intraoperative frozen sections. Chest 
tubes were placed at the end of the procedure and 
removed within 24  hours of confirmation of lung re-
expansion and lack of pleural effusion.
Follow-Up
Follow-up data were collected after the index abla-
tion procedure. For the subgroup who required CSD 
after ablation, follow-up after ablation was censored 
at CSD. End points after ablation and after CSD in-
cluded: (1) any appropriate ICD shock or sustained 
VT below ICD detection; and (2) any VT recurrence 
requiring ICD therapies, including anti-tachycardia 
pacing (ATP). Incidences of death and orthotopic 
heart transplantation (OHT) were also collected to 
evaluate competing risks. ICD interrogations and all 
clinical notes were carefully reviewed to confirm oc-
currence of ATP and appropriate ICD shocks. For 
patients followed at other institutions, referring car-
diologists were contacted and/or electronic medi-
cal records accessing outside centers were used to 
obtain ICD interrogations and clinic notes. All clinical 
follow-up notes and ICD logs were reviewed to en-
sure that ICD shocks and therapies were appropri-
ate and delivered for VT and not for supraventricular 
tachycardia. If any question regarding appropriate-
ness or occurrence of ICD shocks or therapies was 
raised (ie, interrogation was uploaded without elec-
trograms and/or clinical notes did not state whether 
the shock was appropriate), the patient and referring 




In this study, time zero was defined as the time of the 
last (index) ablation at our center. Only a nested sub-
set of patients referred for VT ablation subsequently 
received CSD for arrhythmia recurrence. Since all eli-
gible patients underwent ablation at time 0, a conven-
tional parallel group analysis comparing 2 independent 
groups (those without CSD versus those with CSD) 
at time 0 was not feasible. Instead, the analytical ap-
proach used all of the patient data to create models 
relating key covariates/comorbidities to the outcome 
rates of VT recurrence, sustained VT/ICD shock, or 
mortality/transplant, and then used the data values in 
the CSD subset just before CSD to compute expected 
outcome rates for this subset’s post-CSD follow-up 
(ie, the rates that would be expected if no CSD had 
been performed). This was compared with the actual 
observed outcome rates in the CSD population after 
their CSD.
Descriptive Variables
Continuous variables are presented as mean±SD or 
median (interquartile range [IQR]). Categorical variables 
are presented as counts/percentages. Significance 
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Student t or Mann-Whitney test for continuous and 
chi-square or Fisher exact test for categorical vari-
ables. P≤0.05 was considered statistically significant. 
Computations were performed using SAS 9.4 (SAS 
Institute Inc.) and R3.5.2 (R Project for Statistical 
Computing, www.r-proje ct.org).
Multivariable Models
To compute the expected rate/risk of VT recurrence 
and sustained VT/ICD shocks after ablation adjusted 
for patient comorbidities, Fine-Gray competing risk 
models19 were developed using data at the time of 
presentation for VT ablation from all patients with scar-
mediated MMVT. Predictors of VT recurrences were 
assessed using a Fine-Gray model to control for the 
competing risks of death and transplantation. Patient 
characteristics at the time of VT ablation were used 
for assessment of VT recurrence risk to reduce bias, 
because, at the time of referral for ablation, whether a 
patient would subsequently require CSD at follow-up 
was unknown (eg, a patient could die before undergo-
ing CSD). Potential predictors assessed in the models 
were age, sex, New York Heart Association (NYHA) 
class, LVEF, urgency at presentation, VT storm, car-
diomyopathy, chronic kidney disease, diabetes melli-
tus, and use of ≥2 antiarrhythmic drugs (AADs) before 
ablation. For VT recurrence, variables assessed also 
included acute ablation outcomes (ie, inducibility of 
clinical and nonclinical VTs at the end of the proce-
dure), number of previous VT ablations, and presen-
tation with ICD shock versus ATPs. Predictors of VT 
recurrence/ICD shocks were chosen based on physi-
ological considerations, including previously pub-
lished data on predictors of VT recurrence.20–22 Final 
models minimized the Akaike information criterion. 
Separate models were developed for all VT recur-
rences and sustained VT/ICD shocks. Cox propor-
tional hazard models23 were used to estimate risk of 
death and OHT. The proportional hazard assumption 
for the covariates were assessed via methods by Li, 
Scheike, and Zhang.24
Model-based expected (adjusted) outcomes based 
on risk factors were compared with observed outcomes 
in patients with CSD. While values at the time of VT ab-
lation were used to develop VT recurrence and death/
OHT models, to determine the expected, adjusted event 
rates for outcomes in the subset of patients who under-
went CSD, characteristics (covariate values) at the time 
just before CSD were used, given that for some of these 
variables (ie, NYHA class and LVEF) the value may have 
changed from the time of VT ablation. The P values were 
computed using a modified log-rank test.
Using these multivariable models and the data in 
the subset of patients who underwent CSD, expected 
rates (and corresponding hazard ratios [HRs]) for VT 
recurrence and shocks after CSD were computed and 
compared with the observed VT recurrence rates and 
ICD shock rates (and corresponding HRs) after CSD, 
to quantify the impact of CSD on outcomes in this pop-
ulation (Data S1).
Impact of the Time of Index VT Ablation 
on Outcomes
Because of the relatively longer enrollment period 
(2007–2018), including the more recent routine use 
of contact-force catheters in the past 5 to 6 years, 
the time of the index VT ablation, before 2013 
(2007–2012) versus after 2013 (2013–2018), was 
also specifically evaluated in the models as an ad-




Between January 2007 and December 2018, 381 
consecutive patients (aged 64±13  years, 13% 
women, LVEF 32%±13%; 34% NYHA class III and 
5% NYHA class IV; and 48% nonischemic cardio-
myopathy [NICM]) underwent ablation for scar-me-
diated MMVT. During follow-up, 68 underwent CSD 
(12 had left CSD only). Median time from index VT 
ablation to CSD was 27 days (IQR, 6–114). The sum-
marizes patient characteristics for the entire popu-
lation (n=381) just before ablation, the group who 
received CSD after ablation because of recurrent VT 
(n=68), and the subgroup who did not receive CSD 
(n=313). The most frequent underlying NICM causes 
are also summarized in the Table. Remaining causes 
for NICM included alcoholic/drug-induced cardiomy-
opathy (n=9), familial dilated cardiomyopathy (n=5), 
rheumatic heart disease (n=4), left ventricular non-
compaction (n=2), trauma (n=2), peripartum (n=1), 
chemotherapy-induced (n=1), and Birt-Hogg-Dube 
syndrome (n=1). Seven patients had mixed cardio-
myopathy (cardiomyopathy out of proportion to the 
degree of coronary artery disease).
Compared with the overall population, those who 
were referred for CSD had a higher prevalence of 
NICM (78% versus 48%, P<0.01), presented more 
frequently (at the time of ablation) with VT storm 
(72% versus 47%, P<0.01) and ICD shocks (94% 
versus 84%, P=0.02), and were more likely to have 
NICM caused by sarcoidosis/inflammatory causes 
(9% versus 3%, P=0.03) or hypertrophic (9% versus 
3%, P=0.02) or valvular cardiomyopathy (7% versus 
2%, P=0.02) as compared with other NICM causes. 
They were also more likely to have had a history of 
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The Table and Tables S1 and S2 summarizes clin-
ical and procedural characteristics at the time of VT 
ablation. Compared with the overall study population 
(n=381), patients who received CSD were more likely 
to have multiple (≥3) VT morphologies induced (62% 
versus 43%, P=0.04). At the end of the index abla-
tion procedure, they were also more likely to be both 
inducible for the clinical VT (14% versus 7%) and for the 
nonclinical VTs (25% versus 19%, P=0.03).
Ablation Outcomes
The median follow-up after the index VT ablation 
(n=381) was 15 months (IQR, 2–37 months). The median 
Table 1. Population Characteristics at the Time of Index VT Ablation
Study Cohort 
Undergoing VT Ablation 
(n=381)





(n=313) P Value* P Value†
Age, y 64±13 57±13 65±13 <0.01‡ <0.01‡
Women 48 (13) 8 (12) 40 (13) 0.85 0.82
Ischemic cardiomyopathy 189 (50) 12 (18) 177 (57) <0.01‡ <0.01‡
Nonischemic cardiomyopathy 184 (48) 53 (78) 131 (42) <0.01‡ <0.01‡
Idiopathic 76 (20) 21 (31) 55 (18) 0.04‡ 0.01‡
ARVC 22 (6) 3 (4) 19 (6) 0.65 0.59
Myocarditis 12 (3) 4 (6) 8 (3) 0.26 0.15
Sarcoid/inflammatory 12 (3) 6 (9) 6 (2) 0.03‡ <0.01‡
Hypertrophic 11 (3) 6 (9) 5 (2) 0.02‡ <0.01‡
Valvular 8 (2) 5 (7) 3 (1) 0.02‡ <0.01‡
Chagas 11 (3) 4 (6) 7 (2) 0.20 0.10
Diabetes mellitus 111 (29) 17 (25) 94 (30) 0.49 0.41
Hypertension 241 (63) 43 (63) 198 (63) 1.00 1.00
Hyperlipemia 221 (58) 39 (57) 182 (58) 0.78 0.90
Atrial fibrillation 138 (36) 27 (40) 111 (35) 0.58 0.51
Prior VT ablation before the 
index
192 (50) 43 (63) 149 (48) 0.05 0.02‡
No. of prior VT ablations, median 
(IQR)










LVAD 5 (1) 1 (1) 4 (1) 0.92 0.90
β-Blocker use 322 (85) 63 (93) 259 (83) 0.08 0.04‡
≥2 AAD use 96 (25) 23 (34) 73 (23) 0.14 0.07
Amiodarone use 215 (56) 41 (60) 174 (56) 0.55 0.48
VT storm 179 (47) 49 (72) 130 (42) <0.01‡ <0.01‡




(24, 37, 34, 5)
10/29/28/1 
(15, 43, 41, 1)
83/112/100/18 











LVEF (mean±SD)§ 32±13 33±13 32±13 0.46 0.49
Chronic kidney disease (grade 
≥3)‖
134 (35) 21 (31) 113 (36) 0.49 0.41
Preoperative ECMO/IABP/
Impella
8 (2) 3 (4) 5 (2) 0.17 0.14
AAD indicates antiarrhythmic drug; ARVC, arrhythmogenic right ventricular cardiomyopathy; CRT-D, cardiac resynchronization therapy defibrillator; ECMO, 
extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump; ICD, implantable cardioverter–defibrillator; ICM, ischemic cardiomyopathy; LVAD, left 
ventricular assist device; NICM, nonischemic cardiomyopathy; and NYHA, New York Heart Association.
*Comparison of the cardiac sympathetic denervation (CSD) subgroup to the overall study cohort.
†Comparison of the CSD subgroup to the group that did not undergo CSD (ventricular tachycardia [VT] ablation only). Values are expressed as mean±SD, 
number (percentage), or median (interquartile range).
‡Represent those for which comparisons were statistically significant at P<0.05.
§Data for clinical presentation were available for 378 of 381 patients and for left ventricular ejection fraction (LVEF) for 380 of 381 patients.
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follow-up was censored at CSD in those who under-
went the procedure. Incidence of death/OHT and free-
dom from VT and sustained VT/ICD shocks are shown 
in Figure 1. After the index VT ablation and before CSD, 
VT recurred in 184 patients (48%), including sustained 
VT/ICD shocks in 153 patients (40%). VT and sustained 
VT/ICD shock recurrence was greater in the NICM pop-
ulation (57% and 46% for NICM versus 38% and 29% 
for ischemic cardiomyopathy, respectively; P<0.01).
After the index VT ablation and before CSD, 70 patients 
died (18%) and 23 underwent OHT (6%). Death (n=36) 
or OHT (n=10) occurred without VT recurrence in 46 
patients. The median time to first VT recurrence, OHT, 
and death after the index VT ablation and before CSD 
was 0.5 months (IQR, 0–6), 6 months (IQR, 2–22), and 
1.5 months (IQR, 0.5–10), respectively. The crude rate 
of death/OHT by the end of follow-up was 24% in those 
who did not experience VT recurrences, 39% in those 
who experienced VT recurrence but did not undergo 
CSD, and 49% in those who were referred for CSD for 
VT recurrence (Table S2).
Adjusted competing risk time to event models 
demonstrated that an advanced NYHA class, emer-
gent indication, VT storm, and NICM were inde-
pendently associated with VT recurrence after ablation, 
Figure 2A. Characteristics associated with recurrence 
of sustained VT/ICD shocks are shown in Figure 2B. 
Cox multiple regression models using data at the time 
of index ablation identified advanced NYHA class, 
reduced LVEF, emergent indication for ablation, VT 
storm, chronic kidney disease, and an NICM cause as 
independently associated with death/OHT at follow-up 
(Figure S1). Importantly, outcomes (VT recurrence, ICD 
shocks, or death/OHT) were not influenced by the time 
period of the index VT ablation (between 2007–2013 
versus 2013–2018) (Figures S2 and S3).
Indication for CSD
Indication for CSD in 78% of patients was recurrent 
sustained MMVT (n=27) or ICD shocks (n=26) after 
the last (index) ablation. The remaining patients re-
ceived CSD for occurrence of multiple ATPs for clini-
cal VT (n=3, 4%), frequent episodes of nonsustained 
VT matching the clinical VT (n=2, 3%), or inducibility of 
clinical VT despite their index ablation (n=10, 15%). The 
median time between the index VT ablation procedure 
and CSD was 27 days (IQR, 6–114) and 50% of pa-
tients (n=34) underwent CSD during the same admis-
sion as the index VT ablation. All patients had both the 
index VT ablation and CSD at the same center, and 
referral for CSD was consistent among patients. CSD 
was only performed if the patient was thought to have 
exhausted VT ablation as an option, ie, recurrence of 
Figure 1. Freedom from all ventricular tachycardia (VT) recurrences and sustained VT/
implantable cardioverter–defibrillator (ICD) shocks after ablation.
Freedom from all VT recurrences and from sustained VT/ICD shocks in the overall population (N=381) 
after the index VT ablation. The crude incidence of death and heart transplantation is also shown. OHT 












0 2 4 6 8 10 12 14
Follow up (months) 
Freedom from sustained VT/ICD shock
Freedom from VT recurrence
Death/OHT incidence
Death or transplant      381 260 233 233 207 195 179 165
Sustained VT/Shock  381 226 195 185 172 160 150 137
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arrhythmia despite both endocardial and epicardial 
(when indicated) mapping and ablation. This was par-
ticularly the case for patients who experienced mul-
tiple early recurrences during the same admission 
as the index VT ablation. Tables S1 and S2 demon-
strate the procedural and clinical characteristics of the 
68 patients who underwent CSD and those with VT 
recurrences after VT ablation who were not referred 
for CSD. Patients referred for CSD were younger and 
were more likely to have NICM and a history of VT 
storm and ICD shocks. Nearly two thirds of patients 
referred for CSD had multiple (≥3) VT morphologies in-
duced at the time of the index VT ablation. Finally, there 
was a higher prevalence of hypertrophic and valvular 
Figure 2. Predictors of ventricular tachycardia (VT) recurrences and sustained VT/implantable 
cardioverter–defibrillator (ICD) shocks after the index VT ablation.
Preprocedural characteristics associated with (A) VT recurrence (anti-tachycardia pacing and sustained 
VT/ICD shocks) and (B) sustained VT/ICD shocks alone after VT ablation in the overall population using 
the competing risk models are shown. AAD indicates antiarrhythmic drug; ICD, implantable cardioverter–
defibrillator; LVEF, left ventricular ejection fraction, NICM, nonischemic cardiomyopathy; NYHA, New York 
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cardiomyopathy and a shorter time to VT recurrence in 
the population referred for CSD.
Patient characteristics at the time of CSD ver-
sus the index ablation were not statistically different 
(Table S3).
Expected Versus Observed Outcomes in 
the CSD Group
Median follow-up after CSD was 17  months (IQR, 
4-43 months). At 1 year, freedom from VT recurrence 
and sustained VT/ICD shocks was 65% and 73%, 
Figure 3. Comparison of expected vs observed rates of ventricular tachycardia (VT) recurrence 
after cardiac sympathetic denervation (CSD).
A, Observed: the crude rate of VT recurrences after VT ablation (3.43 per 100 person-months, n=381) and 
after CSD (3.58 per 100 person-months, n=68) are shown above the timeline (arrow). Expected: below the 
timeline (arrow), the expected recurrence rate for the subset of patients who underwent CSD (n=68), as 
estimated from the Fine-Grey model is shown (estimated as if they did not undergo CSD), adjusted for the 
greater comorbidities in this population. The expected rate of VT recurrences calculated from the model for 
the CSD population, adjusted for their comorbidities, was 5.61 per 100 person-months (shown below the 
timeline). Therefore, CSD reduced the expected recurrence rate from 5.61 to 3.58 per 100 person-months. 
The hazard ratio (HR) on top refers to the ratio between the crude rate of VT recurrences after CSD and 
the crude rate of VT recurrences after VT ablation, while the HR on the bottom refers to the expected ratio 
if the patients had not undergone CSD. Therefore, CSD led to a lower than expected HR. B, The adjusted 
expected vs observed cumulative VT recurrence risk rates are shown. CSD significantly reduced the 
observed vs expected HR for all VT recurrences by >30%. The observed curves account for the competing 
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respectively, in the CSD group. At the end of follow-
up, 19 patients died (28%) and 14 underwent OHT 
(21%). In 6 patients (9%), death (n=4) or OHT (n=2) 
occurred without VT recurrence.
Model-based expected VT recurrence rate ad-
justed for comorbidities in the CSD group was 5.61 
per 100 person-months, while the actual observed 
post-CSD rate was 3.58 per 100 person-months. For 
sustained VT/ICD shocks, the expected hazard rate 
was 4.34, while the observed rate was 2.85 per 100 
person-months. Therefore, CSD reduced expected 
rates for VT recurrence and ICD shocks by 36% and 
Figure 4. Comparison of expected vs observed rates of sustained ventricular tachycardia (VT)/
implantable cardioverter–defibrillator (ICD) shocks after cardiac sympathetic denervation (CSD).
A, Observed: the crude rate of sustained VT/ICD shocks after VT ablation (2.61 per 100 person-months, 
n=381) and after CSD (2.85 per 100 person-months, n=68) are shown above the timeline (arrow). Expected: 
below the time line (arrow) the model estimated expected adjusted sustained VT/ICD shocks recurrence 
rate for the subset of patients who underwent CSD (n=68) is shown, as if they had not undergone CSD. 
The expected rate of sustained VT/ICD shocks calculated from the model based on patient comorbidities 
was 4.34 per 100 person-months. The observed rate after CSD was reduced to 2.85 per 100 person-
months. The hazard ratio (HR) above the arrow refers to the ratio between the crude rate of sustained VT/
ICD shocks after CSD and the crude rate of sustained VT/ICD shocks after VT ablation, while the HR on 
the bottom of the arrow refers to the expected ratio if patients had not undergone CSD as estimated by 
the Fine-Grey model based on their greater comorbidities. Therefore, CSD led to a lower then expected 
HR. B, Expected and observed sustained VT/ICD shock cumulative risk curves over time after CSD 
are shown. The observed cumulative curves account for the competing risk of death/orthotopic heart 
transplantation. CSD significantly reduced the observed vs expected HR for sustained VT/ICD shocks. 
Dashed lines represent the standard error of each curve.
After VT ablation (n=381) After CSD (n=68)
Crude rate (100 person-mos) Crude rate (100 person-mos)
Observed
Sustained VT/ICD Shock 2.61 2.85 1.09
Expected (Model)
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34%, respectively. The expected HR for recurrent VT 
and sustained VT/ICD shocks, after adjusting for co-
morbidities, was 1.64 (95% CI, 1.40–1.91) and 1.67 
(95% CI, 1.41–1.97), respectively (Figures 2A and 3A). 
Observed HRs after CSD were 1.04 and 1.09, respec-
tively. In line with the above, therefore, CSD modified 
VT recurrence HRs by 36% (observed/expected HR, 
0.64; 95% CI, 0.45–0.90 [P=0.01]) (Figure  3) and 
sustained VT/ICD shock HRs by 34% (observed/
expected HR, 0.66; 95% CI, 0.45–0.96 [P=0.03]) 
(Figure 4). Expected versus observed HRs for death/
OHT were not significantly different (observed/ex-
pected HR, 1.17; 95% CI, 0.74–1.86 [P=0.49]). Finally, 
major complications after CSD were observed in 5 
patients (7%), including deep venous thromboembo-
lism on postoperative day 2 (n=1), hemothorax (n=1) 
and pneumothorax (n=1), transient paralysis of the 
left phrenic nerve (n=1), and transient acute respi-
ratory failure in the setting of severe amiodarone-in-
duced lung toxicity (n=1). Minor complications/side 
effects of the procedure are detailed in Table S4.
ICD Shock and VT Burden in the CSD 
Population
The median number of sustained VT/ICD shocks in the 
12  months before CSD was 10 (IQR, 5–18) versus 1 
(IQR, 0–4) in the 12 months after follow-up (median re-
duction of 94%, P<0.0001) (Figure 5) and 2 (IQR 0–6) 
at last available follow-up (median of 17 months; IQR, 
4–43  months [P<0.0001]). The median number of all 
VT episodes (sustained VT/ICD shocks/ATP) in the 
12 months before CSD was 16.5 (IQR, 9–31) compared 
with 2 (IQR, 0–9) in the 12 months after follow-up (me-
dian reduction of 81%, P<0.0001) (Figure 6) and 4 (IQR, 
1–12; P<0.0001 versus before CSD) at last available fol-
low-up (median of 17 months; IQR, 4–43 months) after 
CSD. CSD reduced VT burden similarly in patients with 
ischemic cardiomyopathy versus those with NICM at 
12  months (Figure  7). In the short period (median of 
27 days) between the index VT ablation and CSD, the 
median number of VT episodes in patients referred for 
CSD was 5 (IQR, 1–12) and the median number sus-
tained VT/ICD shocks was 4 (IQR, 1–7).
Figure 5. Sustained monomorphic ventricular tachycardia (VT)/implantable cardioverter–
defibrillator (ICD) shocks 12 months before vs after cardiac sympathetic denervation (CSD).
Number of sustained VT episodes and appropriate ICD shocks per person in the 12 months before vs the 
12 months after CSD (n=68). The median number of sustained VT episodes and shocks was reduced from 
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Before CSD, 90% of patients were taking oral AADs 
(62% on amiodarone). At last available follow-up, 81% 
of patients were taking AADs (59% on amiodarone). 
The mean dosage of amiodarone per patient de-
creased from 391±195 to 298±197 mg (P=0.02).
DISCUSSION
Major Findings
This study demonstrates that although patients with 
scar-mediated MMVT who subsequently require CSD 
after extensive and often multiple VT ablations were at 
higher risk of VT recurrence after ablation because of 
their baseline comorbidities, CSD significantly decreased 
the expected adjusted rates of VT recurrence and ICD 
shocks as well as VT burden. An emergent indication for 
ablation was an independent predictor of both mortality/
OHT and VT recurrence, alluding to the importance of 
early referral for ablation and CSD.
A competing risk model was used in this study to 
estimate the relationship between patient factors and 
VT recurrence risk in those with scar-mediated MMVT 
referred for ablation. This model was then utilized to 
estimate the expected risk of VT recurrence in patients 
referred for CSD, adjusting for their comorbidities. This 
adjusted risk was compared with the actual observed 
outcomes after CSD, to quantify the impact of the 
procedure.
Propensity score matching was not used in this 
study because of the inability to create a parallel de-
sign. All patients who underwent CSD also had a prior 
VT ablation, and nearly all patients had experienced 
a recurrence after VT ablation before receiving CSD. 
Therefore, a comparison of outcomes of patients with 
CSD only, adjusting for covariates, to those with VT 
ablation only was not appropriate. We also could not 
evaluate CSD as a covariate in a single Cox or Fine-
Gray model for this same reason. All patients were at 
risk for death/transplantation, VT recurrence, and ICD 
shock, and these sometimes occurred before CSD. 
CSD was, in fact, given at least in part because of the 
deteriorating cardiovascular condition as indicated by 
arrhythmia recurrences before CSD, if the patient was 
Figure 6. Monomorphic ventricular tachycardia (VT) episodes 12 months before vs after cardiac 
sympathetic denervation (CSD).
All VT episodes (inculding sustained VT/anti-tachycardia pacing (ATP)/implantable cardioverter–
defibrillator [ICD] shocks) in the 12 months before CSD vs the 12 months after CSD. The median number 
of ATPs, sustained VT, and ICD shock episodes was significantly reduced in the 12 months after CSD as 
compared with the 12 months before CSD (from a median of 16.5 [interquartile range (IQR), 9–31 episodes 
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alive and not transplanted. In addition, time-dependent 
covariates/characteristics such as LVEF, NYHA class, 
VT storm, and hemodynamic stability are dynamic 
and may change over time (ie, at presentation for VT 
ablation as compared with the presentation for CSD). 
We found that CSD reduced the risk of sustained VT/
ICD shocks as well as all VT recurrences by >30% in 
patients with scar-mediated MMVT and a previous VT 
ablation, a novel finding of this study. To our knowl-
edge, this is the first assessment of the value of CSD in 
this particular population, which is much more preva-
lent in clinical practice, than patients with polymorphic 
VT. The results quantify the expected benefits of CSD, 
which is critical in understanding the clinical impact 
of this procedure. Importantly, in this study CSD was 
not performed as an alternative to conventional redo 
VT ablation. Rather, CSD was performed as a bailout 
strategy in patients with a recent VT ablation (referred 
to as index) performed at our center, and patients were 
referred for CSD only if the referring physican expected 
that another VT ablation procedure would be futile, 
given findings of the most recent/index ablation.
Quantifying the Impact of CSD in MMVT
In previous case series of patients with SHD and re-
fractory VT/VF who underwent CSD, including the 
largest series of 121 patients, 25% to 50% presented 
with polymorphic VT or VF.5–10 Therefore, at least part 
of the benefit of CSD at follow-up was presumed to 
have been driven from the polymorphic VT population, 
and the effect of CSD in the setting of MMVT remained 
controversial. In this study, patients with any evidence 
of spontaneous polymorphic VT or idiopathic VF were 
excluded, in order to specifically assess the value of 
CSD in patients with scar-realted MMVT.
In addition, in previous case series, patients un-
dergoing CSD had significant comorbidities, which 
could have affected their outcomes and risk of VT 
recurrence after ablation.5–11 Published studies have 
relied on comparing burden of ICD shocks before 
versus after CSD, without adjusting for comorbidities. 
Therefore, the true impact of CSD on VT recurrence 
over time remained unknown. Knowing this rate/risk 
is critical in physician and patient discussion of risks 
and expected procedural benefit. In this study, char-
acteristics at the time of presentation for VT ablation 
were used to develop multivariable models, as at this 
time point, whether a patient would subsequently 
require CSD was unknown. While the models were 
developed to estimate rates of VT recurrence using 
data from all patients and values at the time of the 
index ablation, expected HRs for the CSD popula-
tion were computed using values of covariates at the 
time of presentation for CSD, reflecting this group’s 
Figure 7. Ventricular tachycardia (VT) episodes 12 months before vs after cardiac sympathetic 
denervation (CSD) according to underlying type of cardiomyopathy.
VT episodes in the 12  months before as compared with the 12  months after CSD according to the 
underlying cardiomyopathy type. No difference was found when comparing the reduction for all VT 
episodes and sustained VT/implantable cardioverter–defibrillator shocks between patients with ischemic 




 http://ahajournals.org by on A
pril 13, 2021
J Am Heart Assoc. 2021;10:e018371. DOI: 10.1161/JAHA.120.018371 13
Dusi et al Bailout Sympathetic Denervation for Monomorphic VT
expected risk, while considering the dynamic nature 
of their disease. It is this adjusted rate and HR (cal-
culated as if the 68 patients had not undergone CSD) 
that was compared with the observed rate and HR 
after CSD. This comparison demonstrated that CSD 
reduces the rate of sustained VT/ICD shocks by 34% 
and of all VT recurrences by 36%. Many of the fac-
tors associated with both VT recurrence and death/
OHT in our model have also been validated in other 
studies,20–22,25,26 confirming that the models used in 
this study were robust in measuring risk and rates of 
outcomes after ablation.
Risk of VT Recurrence, ICD Shocks, 
Death, and OHT
In this study, patients who subsequently underwent 
CSD had more severe comorbidities, including a 
more advanced NYHA class, history of VT storm, and 
a higher number of previous ablations, even at the 
time of their index procedure. They were more likely 
to have causes of NICM associated with a greater 
risk of VT recurrence after ablation,20 including HCM, 
sarcoidosis, and valvular heart disease. These sub-
types of NICM often harbor a more challenging VT 
substrate, including intramural and epicardial scars, 
leading to the observed poorer outcomes after abla-
tion compared with both ischemic cardiomyopathy 
and idiopathic dilated cardiomyopathy.20 In line with 
other studies, this study shows that a higher NYHA 
class, use of ≥2 AADs, NICM, and VT storm are in-
dependently associated with risk of VT recurrence 
after ablation, resulting in the higher expected/ad-
justed risk of VT recurrence in the subgroup requir-
ing CSD.20–22,25
Type of admission (elective versus urgent/emer-
gent) has been associated with increased in-hospital 
mortality and adverse events after VT ablation.26 To 
the best of our knowledge, this is the first time an 
emergent indication is also recognized as an inde-
pendent predictor of arrhythmia recurrence after VT 
ablation. Of note, the predictive value of an emer-
gent indication was independent of NYHA functional 
class.
Management of Refractory MMVT
Catheter ablation reduces VT burden in patients with 
SHD.27,28 Despite significant technical progress, how-
ever, VT recurrence rates after ablation remain nota-
ble, especially in patients with NICM.20,25 Uptitration 
of AADs is of limited value because of toxicity and 
lack of efficacy often despite higher doses.28,29 This 
study demonstrates that in patients with scar-medi-
ated MMVT, despite at least 1 (often extensive) VT 
ablation procedure, CSD provided additional benefit. 
In addition, the reduction in VT burden after CSD was 
independent of the underlying type of cardiomyopa-
thy (ischemic cardiomyopathy versus NICM).
Limitations
This is a single-center retrospective study represent-
ing outcomes at a tertiary referral center. ICD pro-
gramming was left to the discretion of the treating 
physician and, therefore, was not uniform among 
patients. Although surgical techniques for CSD re-
mained unchanged over the study period, VT abla-
tion techniques may have evolved over time. In this 
cohort, however, a comparison of the first 5 versus 
the past 5 years of the study did not show a differ-
ence in outcomes. It should be recognized that the 
computed expected outcome rates assume that our 
models capture the essential comorbidity variables 
and covariates. Since this study consisted of only 68 
patients with scar-mediated MMVT who underwent 
CSD, future validation is needed using a larger sam-
ple of patients.
CONCLUSIONS
This study demonstrates that patients with drug and 
ablation refractory scar-mediated MMVT who require 
CSD are at a higher risk of VT recurrence after abla-
tion as compared with patients not referred for CSD, 
predominantly because of their higher prevalence of 
NICM and other comorbidites. In this population, CSD 
significantly decreased both the expected rates of ar-
rhythmia recurrences and VT burden. An emergent 
indication for VT ablation is an independent predictor 
for both mortality/OHT and arrhythmia recurrence, al-
luding to the importance of early referral for ablation 
and CSD.
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Observed VT rates: Total VT recurrences (including ATPs) and sustained VT/ICD shock 
rates after the index ablation and before CSD were determined as number of events 
divided by the total person-time at risk. Rates for these outcomes after CSD were 
determined similarly. Observed hazard ratio (HR) after CSD was calculated as the ratio 
between the actual post-CSD events rate (per 100 person/months) and the pre-CSD, 
post-ablation event rate (per 100 person/months). 
The Fine-Gray competing risk model 21 using variables from all subjects (n=381) 
was used to estimate rates of VT recurrences (including ATPs and sustained VT/ICD 
shocks) as well as sustained VT/ICD shocks alone before CSD, where death and 
transplantation were controlled for as a competing risk. Cox proportional hazard model 22 
using variables on all subjects at risk (n=381) at the time of the index VT ablation was 
used to model death/OHT rates before CSD. These models provided a (relative) risk 
score for VT recurrence and ICD shock outcomes in log hazard units. The antilog of the 
difference in risk score using values for covariates at the time of the CSD procedure minus 
values at the time of the index VT ablation resulted in the expected post-CSD to pre-CSD 
hazard ratio (HR). Values of the expected HRs to the observed HRs were compared to 
determine whether the expected post-CSD versus the observed post-CSD outcome rates 








Missing data: Complete data on all variables for the 381 patients used in the study was 
available for analysis, with the exception of 4 patients (1%) that did not have LVEF and/or 
type of presentation documented at the time of VT ablation. For these variables, the 










Table S1. Procedural Characteristics. 
 
*Comparison of the CSD subgroup to the overall study cohort. †Comparison of CSD subgroup to the group 
that did not undergo CSD (had VT ablation only). **Comparison between those with recurrences after the 
index VT ablation who did (n=68) and did not (n=116) undergo CSD.  Values are n (%). Bold values represent 
those for which comparisons were statistically significant at p value < 0.05. CSD = cardiac sympathetic 
denervation ECMO= extracorporeal membrane oxygenator; IABP = intra-aortic balloon pump; VT = 
ventricular tachycardia. ‡Number of induced VTs during the VT ablation procedure was available for 363 of 
381 and for 60 of 68 patients, respectively, while data of VT inducibility at the end of the ablation procedure 





 Entire study 
Cohort 
(n=381) 
CSD Post-ablation due 
to VT recurrence 
(n=68) 
VT Ablation without 











Epicardial access 192 (50) 38 (56) 154 (49) 0.68 0.32 64 (55) 0.92 
Epicardial ablation 138 (36) 24 (35) 114 (36) 0.88 0.86 45 (39) 0.64 
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(ECMO, IABP, Impella)  
31 (8) 2 (3) 29 (9) 0.13 0.08 11 (9) 0.09 








TableS2. Patient Characteristics at Index VT ablation and Outcomes by VT 
Recurrence and CSD. 
 
 
* Comparison between those with recurrences after the index VT ablation who did (n=68) and did not (n=116) undergo 
CSD. †Comparison of the CSD subgroup (n=68) to the subgroup who did not suffered recurrences after the index VT 
ablation (n=197). Values are mean ± SD, n (%), or median (interquartile range). Bold values represent those for which 
comparisons were statistically significant at p value < 0.05. AAD = antiarrhythmic drugs; ARVC = arrhythmogenic right 

















Age (years) 57±13 64 ± 13 <0.01 66 ± 12 <0.01 
Female 8 (12) 18 (16) 0.48 22 (11) 0.20 






















































Diabetes mellitus 17 (25) 34 (29) 0.53 60 (30) 0.39 
Hypertension 43 (63) 71 (61) 0.78 111 (56) 0.32 
Hyperlipemia 39 (57) 78 (67) 0.18 104 (53) 0.51 
Atrial fibrillation 27 (40) 38 (33) 0.34 73 (37) 0.70 
Prior VT ablation 
before the index 
43 (63) 57 (49) 0.06 92 (47) 0.02 
Number of prior VT ablations before 
index VT ablation (median, IQR) 




(None, ICD, CRT-D) 
1/44/23 
(1, 65, 34) 
10/80/26 
(9, 69, 22) 
0.05 
13/109/75 
(7, 55, 38) 
0.17 
LVAD 1 (1) 2 (2) 0.90 2 (1) 0.76 
Beta-blocker use 63 (93) 99 (85) 0.14 160 (81) 0.26 
≥ 2 AAD use 23 (34) 28 (24) 0.16 45 (23) 0.07 
Amiodarone 41 (60) 63 (54) 0.43 111 (56) 0.57 
VT Storm 49 (72) 52 (45) <0.01 78 (40) <0.01 




(15, 43, 41, 1) 
32/41/37/6 
(28, 35, 32, 5) 
0.10 
51/71/63/12 










(29, 70, 1) 
0.37 
LVEF (mean±SD)‡ 33 ± 13 31 ± 13 0.23 33 ± 13 0.66 
CKD (Grade ≥3) § 21 (31) 34 (29) 0.82 80 (41) 0.15 
Pre-operative ECMO/IABP/Impella 3 (4) 0 (0) 0.09 5 (2) 0.43 
Time from index VT ablation to first 
recurrence, days (median, IQR) 
             4 (1-39)      39 (5-490)            <0.01  
 
Death/OHT by the end of FU 33 (49) 45 (39) 0.19 48 (24) <0.01 
Time from index VT ablation to 
death/OHT, days (median, IQR) 








sympathetic denervation; ECMO = extracorporeal membrane oxygenator; IABP= intra-aortic balloon pump; ICD = 
Implantable cardioverter-defibrillator; ICM = ischemic cardiomyopathy; LCSD = left cardiac sympathetic denervation; 
LVAD = left ventricular assist device; LVEF = left ventricular ejection fraction, NICM = nonischemic cardiomyopathy; 
NYHA = New York Heart Association; OHT = orthotopic heart transplant. VT = ventricular tachycardia. ‡Data about 









Table S3. Characteristics at the Time of VT Ablation vs. CSD.  
 




Age  57 ±13 57±13 
LVEF  33±13 34±12 
VT storm 49 (72) 52 (76) 
   
CKD 21 (31) 25 (36) 
   
≥ 2 AAD use 23 (33) 23 (33) 
   
NYHA Class   
   NYHA Class I 10 (15) 8 (12) 
   NYHA Class II 29 (43) 33 (49) 
   NYHA Class III 28 (41) 23 (33) 
   NYHA Class IV 1 (1) 4 (6) 
Elective indication 18 (27) 17 (25) 
Urgent indication 46 (68) 48 (71) 
Emergent indication 3 (4) 3 (4) 
Values are mean ± SD, n (%), or median (interquartile range). AAD = antiarrhythmic 
drugs; CKD = chronic kidney disease; CSD = cardiac sympathetic denervation; LVEF = 
left ventricular ejection fraction; NICM= nonischemic cardiomyopathy; NYHA = New York 















Table S4. Minor complications after CSD.  
Type of complication Number of  
patients, (%) 
Management 
Ptosis   
- Transient * 





No specific treatment   
Abnormal skin 
sensitivity/neuropathic pain 
- Transient * 






pregabalin as needed 
Compensatory hyperhidrosis 7 (10) No specific treatment 








Figure S1. Pre-procedural characteristics found to be independently associated 




















Emergent indication  
NYHA class II
NYHA class III or IV 










Figure S2. Freedom from VT recurrence (panel A) and from sustained VT/ICD 

























Figure S3. Incidence of death/OHT (orthotopic heart transplant) by index VT 
ablation time period (2007 to 2012 vs. 2013 to 2018). 
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